Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Yukari Uemura, Teruki Sone, Shiro Tanaka, Teruhiko Miyazaki, Mayumi Tsukiyama, Akira Taguchi, Satoshi Soen, Satoshi Mori, Hiroshi Hagino, Toshitsugu Sugimoto, Masao Fukunaga, Hiroaki Ohta, Toshitaka Nakamura, Hajime Orimo & Masataka Shiraki. (2020) Randomized head-to-head comparison of minodronic acid and raloxifene for fracture incidence in postmenopausal Japanese women: the Japanese Osteoporosis Intervention Trial (JOINT)-04. Current Medical Research and Opinion 36:11, pages 1847-1859.
Read now
Read now
Gustavo Duque. (2013) Osteoporosis in older persons: current pharmacotherapy and future directions. Expert Opinion on Pharmacotherapy 14:14, pages 1949-1958.
Read now
Read now
Alex Fisher, Jodie Martin, Wichat Srikusalanukul & Michael Davis. (2010) Bisphosphonate use and hip fracture epidemiology: ecologic proof from the contrary. Clinical Interventions in Aging 5, pages 355-362.
Read now
Read now
Articles from other publishers (17)
Mina Nicole Händel, Isabel Cardoso, Cecilie von Bülow, Jeanett Friis Rohde, Anja Ussing, Sabrina Mai Nielsen, Robin Christensen, Jean-Jacques Body, Maria Luisa Brandi, Adolfo Diez-Perez, Peyman Hadji, Muhammad Kassim Javaid, Willem Frederik Lems, Xavier Nogues, Christian Roux, Salvatore Minisola, Andreas Kurth, Thierry Thomas, Daniel Prieto-Alhambra, Serge Livio Ferrari, Bente Langdahl & Bo Abrahamsen. (2023) Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials. BMJ, pages e068033.
Crossref
Crossref
George A Wells, Shu-Ching Hsieh, Carine Zheng, Joan Peterson, Wenfei Liu, Shannon E Kelly & Peter Tugwell. (2022) Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database of Systematic Reviews 2022:7.
Crossref
Crossref
Nils Becker, Tobias Hafner, Miguel Pishnamaz, Frank Hildebrand & Philipp Kobbe. (2022) Patient-specific risk factors for adverse outcomes following geriatric proximal femur fractures. European Journal of Trauma and Emergency Surgery 48:2, pages 753-761.
Crossref
Crossref
Jad G Sfeir & Robert J Pignolo. (2021) Pharmacologic Interventions for Fracture Risk Reduction in the Oldest Old: What Is the Evidence?. JBMR Plus 5:10.
Crossref
Crossref
Vasi Naganathan & Kujan Nagaratnam. 2019. Advanced Age Geriatric Care. Advanced Age Geriatric Care
217
221
.
Michael R. McClung, Nicholas C. Harvey, Lorraine A. Fitzpatrick, Paul D. Miller, Gary Hattersley, Yamei Wang & Felicia Cosman. (2018) Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis. Menopause 25:7, pages 767-771.
Crossref
Crossref
Eric Kai-Chung Wong & Alexandra Papaioannou. (2018) Postmenopausal Osteoporosis Treatment Update. Current Treatment Options in Rheumatology 4:2, pages 142-157.
Crossref
Crossref
Eric Kai-Chung Wong, Lisa Ha-Yeon Kim & Alexandra Papaioannou. 2016. Osteoporosis in Older Persons. Osteoporosis in Older Persons
201
214
.
Zhiyun Feng, Shumei Zeng, Yue Wang, Zhiyun Zheng & Zhong Chen. (2013) Bisphosphonates for the Prevention and Treatment of Osteoporosis in Patients with Rheumatic Diseases: A Systematic Review and Meta-Analysis. PLoS ONE 8:12, pages e80890.
Crossref
Crossref
Vivian K. Kawai, Carlos G. Grijalva, Patrick G. Arbogast, Jeffrey R. Curtis, Daniel H. Solomon, Elizabeth Delzell, Lang Chen, Rita Ouellet-Hellstrom, Lisa Herrinton, Liyan Liu, Edward F. MitchellJr.Jr., C. Michael Stein & Marie R. Griffin. (2013) Initiation of Tumor Necrosis Factor α Antagonists and Risk of Fractures in Patients With Selected Rheumatic and Autoimmune Diseases. Arthritis Care & Research 65:7, pages 1085-1094.
Crossref
Crossref
Rebecca L. Dunn, Matthew L. Bird, Susan E. Conway & Mark A. Stratton. (2013) Use of Bisphosphonates in Older Adults: How Long Is Long Enough?. The Consultant Pharmacist 28:1, pages 39-57.
Crossref
Crossref
Charles A. Inderjeeth, Kien Chan, Kevin Kwan & Michelle Lai. (2012) Time to onset of efficacy in fracture reduction with current anti-osteoporosis treatments. Journal of Bone and Mineral Metabolism 30:5, pages 493-503.
Crossref
Crossref
M. Osaki, K. Tatsuki, T. Hashikawa, T. Norimatsu, K. Chiba, S. Motokawa, I. Furuichi, Y. Doiguchi, K. Aoyagi & H. Shindo. (2011) Beneficial effect of risedronate for preventing recurrent hip fracture in the elderly Japanese women. Osteoporosis International 23:2, pages 695-703.
Crossref
Crossref
Brian J. GatesShyamal Das. (2012) Risedronate's Role in Reducing Hip Fracture in Postmenopausal Women with Established Osteoporosis. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders 5, pages CMAMD.S4092.
Crossref
Crossref
Wei Mei Chua, Novoneel Nandi & Tahir Masud. (2011) Pharmacological treatments for osteoporosis in very elderly people. Therapeutic Advances in Chronic Disease 2:4, pages 279-286.
Crossref
Crossref
Jeroen P. Jansen, Gert J.D. Bergman, Jasper Huels & Melvin Olson. (2011) The Efficacy of Bisphosphonates in the Prevention of Vertebral, Hip, and Nonvertebral-Nonhip Fractures in Osteoporosis: A Network Meta-Analysis. Seminars in Arthritis and Rheumatism 40:4, pages 275-284.e2.
Crossref
Crossref
Charles A Inderjeeth & Kate E Poland. (2010) Management of Osteoporosis in Older People. Journal of Pharmacy Practice and Research 40:3, pages 229-234.
Crossref
Crossref